Adamis Recalls Four Lots of Symjepi
The recall was related to syringes in these lots malfunctioning.
Adamis Pharmaceuticals is voluntarily recalling certain lots of Symjepi (epinephrine) injection, which is used for the emergency treatment of allergic reactions, including anaphylaxis to stinging insects and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.
The lots impacted by the recall include 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) pre-filled single-dose syringes. The products are packaged in two per carton and were distributed nationwide and directly to customers and/or medical facilities. The products can be identified by the label containing the US WorldMeds name and logo pictured on the cartons below. US WorldMeds markets and distributes Symjepi in the United States, under license from Adamis.
The recall was related to syringe malfunctioning in these lots. Although not confirmed to be related to the recall, there have been two customer complaints on three syringes, regarding difficulty in dispensing the product. The companies are not aware of any adverse events related to this recall.
The lots impact by the recall are:
- Lot number 21101Y with an expiration date of November 30, 2022; NDC 78670-131-02; 0.15 mg/0.3 mL
- Lot number 21041W with an expiration date of August 31, 2022; NDC 78670-130-02; 0.3 mg/0.3 mL
- Lot number 21081W with an expiration date of November 30, 2022; NDC 78670-130-02; 0.3 mg/0.3 mL
- Lot number 21102W with an expiration date of February 28, 2022; NDC 78670-130-02; 0.3 mg/0.3 mL
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
